BioInvent focuses its business

Lund, Sweden – 2 October 2012 – BioInvent International AB (OMXS:BINV) announces
today that the company has decided to focus its operations with the aim of
achieving self-financing of the business before external costs for future new
clinical studies. Its development of proprietary antibody drugs will concentrate
primarily on developing new cancer drugs, resulting in a clear indication focus.
The company currently has five agreements with major companies based on products
from the antibody library, n-CoDeR®. The company will increase the efforts to
create new n‑CoDeR agreements for clinical programmes and continue to develop
existing partnerships.

Next year the company’s expenses will be reduced to around SEK 75 million. The
aim is to balance these costs with revenues from external programmes.

In July 2012 the number of full-time employees was reduced by 21. The company
now intends to reduce the number of full-time employees by a further 20 people
in a second phase. The number of full-time employees will thus have been reduced
from 89 to 48 during the year. Following the changes, 39 full-time employees
will work in research and development.

Svein Mathisen, President and CEO of BioInvent, comments: “We are moving from
being active in a number of medical areas to focusing primarily on cancer, such
as BI‑505, currently in clinical phase I, for the treatment of multiple myeloma,
and on two new drug candidates for which preclinical development is expected to
start with toxicology studies during summer next year. We intend to partner our
programmes at an early stage.

We see good opportunities to increase revenues from our external programmes,
thereby achieving a significant increase in the self-financing of our
operations. As the drug candidates from our partnerships advance through
clinical development BioInvent will receive milestone payments. We expect
clinical studies of at least two product candidates from existing partnerships
to start as early as next year.”

Svein Mathisen continues: “We regret the fact that the changes in our
organisation will impact our employees. However, we are convinced that focusing
the business will strengthen the company and our long-term development.”

The company has initiated negotiations in accordance with the Swedish
Codetermination Act in respect of the planned personnel changes.

  - END –

To the editors:

About BioInvent
BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a
research-based pharmaceutical company that focuses on developing antibody drugs.
The Company currently has clinical development projects within the areas of
cancer and atherosclerosis. The Company has signed various strategic alliances
to strengthen the product pipeline and increase the likelihood of success. These
partners include Genentech, Human Genome Sciences and ThromboGenics.

The company’s competitive position is underpinned by n-CoDeR®, a proprietary
antibody development platform. The scope and strength of this platform is also
utilised by partners, such as Bayer HealthCare, Daiichi Sankyo, Mitsubishi
Tanabe and Servier. More information is available at www.bioinvent.com.

For further information, please contact:

BioInvent International AB
Svein Mathisen
President & CEO
Phone:+46 (0)46 286 85 67
Mobile: +46 (0)708 97 82 13
E-mail: svein.mathisen@bioinvent.com

BioInvent International AB (publ)
Co. reg. No. 556537-7263,
Visiting address: Sölvegatan 41
Mailing address: SE-223 70 LUND
Phone: +46 (0)46 286 85 50
info@bioinvent.com
www.bioinvent.com

Legal disclaimer
The press release contains statements about the future, consisting of subjective
assumptions and forecasts for future scenarios. Predictions for the future only
apply as the date they are made and are, by their very nature, in the same was
as research and development work in the biotech segment, associated with risk
and uncertainty. With this in mind, the actual outcome may deviate significantly
from the scenarios described in this press release.

Information disclosed in this press release is provided herein pursuant to the
Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading
Act. The information was submitted for publication at 8.55 a.m. CET, on 2
October, 2012.